Analysis in human immunodeficiency virus type 1 vectors of cis-acting sequences that affect gene transfer into human lymphocytes.

Recombinant human immunodeficiency virus type 1 (HIV-1) strains containing sequences from different viral genetic subtypes (intersubtype) and different lineages from within the

Lentivirus vectors based on human immunodeficiency virus (HIV) type 1 (HIV-1) constitute a recent devel- opment in the field of gene therapy.. A key property of HIV-1-derived vectors

Intracellular expression of RNA transcripts complementary to the human immunodeficiency virus type 1 gag gene inhib- its viral replication in human CD4 1 lymphocytes.

In human immunodeficiency virus type 1 (HIV-1), deletions in the un- translated leader region (UTR), between the major splice do- nor and the gag initiation codon, identified a

EBV infection resulted in enhanced replication of human immunodeficiency virus type 1 (HIV-1) IIIB in CD4 1 lymphocytes as measured by accumulation of reverse transcriptase

A human immunodeficiency virus type 1 (HIV-1)-based retro- viral vector system utilizing stable HIV-1 packaging cell lines. Optimal infectivity in vitro of human immunodeficiency

To generate nonpathogenic viral particles which express active human immunodeficiency virus type 1 (HIV-1) protease (PR), plasmids containing sequences from the genomes of HIV-1

The expression of human immunodeficiency virus type 1 (HIV-1) in human cells is regulated by viral protein factors.. rev interacts with a cis-acting element in the env region that